Document is current
Any future updates will be listed below
-
Authors
Rollot, Fabien https://orcid.org/0000-0002-5752-2331
Couturier, Justine
Casey, Romain
Wiertlewski, Sandrine
Debouverie, Marc
Pelletier, Jean
De Sèze, Jérôme
Labauge, Pierre
Ruet, Aurélie
Thouvenot, Eric
Ciron, Jonathan
Berger, Eric
Gout, Olivier
Clavelou, Pierre
Stankoff, Bruno
Casez, Olivier
Bourre, Bertrand
Zephir, Hélène
Moreau, Thibault
Lebrun-Frenay, Christine
Maillart, Elisabeth
Edan, Gilles
Neau, Jean-Philippe
Montcuquet, Alexis
Cabre, Philippe
Camdessanché, Jean-Philippe
Defer, Gilles
Nasr, Haifa Ben
Maurousset, Aude
Hankiewicz, Karolina
Pottier, Corinne
Leray, Emmanuelle
Vukusic, Sandra
Laplaud, David-Axel
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-COHO-002)
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
Journal Title: Neurotherapeutics
CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-022-01202-1
Content Type: article
Copyright: Copyright © 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.
